These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37877369)

  • 41. Miniature Palpebral Plexiform Neurofibroma in Neurofibromatosis Type 2.
    Charles NC; Kim ET
    Ophthalmic Plast Reconstr Surg; 2023 Nov-Dec 01; 39(6):e186-e188. PubMed ID: 37338324
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quantitative associations of scalp and body subcutaneous neurofibromas with internal plexiform tumors in neurofibromatosis 1.
    Jett K; Nguyen R; Arman D; Birch P; Chohan H; Farschtschi S; Fuensterer C; Kluwe L; Friedman JM; Mautner VF
    Am J Med Genet A; 2015 Jul; 167(7):1518-24. PubMed ID: 25900062
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of growth hormone receptor in plexiform neurofibromas of patients with neurofibromatosis type 1.
    Cunha KS; Barboza EP; Fonseca EC
    Clinics (Sao Paulo); 2008 Feb; 63(1):39-42. PubMed ID: 18297205
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical and humanistic burden among pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma in the USA.
    Yang X; Yoo HK; Amin S; Cheng WY; Sundaresan S; Zhang L; Duh MS
    Childs Nerv Syst; 2022 Aug; 38(8):1513-1522. PubMed ID: 35579709
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.
    Armstrong AE; Belzberg AJ; Crawford JR; Hirbe AC; Wang ZJ
    BMC Cancer; 2023 Jun; 23(1):553. PubMed ID: 37328781
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.
    Widemann BC; Dombi E; Gillespie A; Wolters PL; Belasco J; Goldman S; Korf BR; Solomon J; Martin S; Salzer W; Fox E; Patronas N; Kieran MW; Perentesis JP; Reddy A; Wright JJ; Kim A; Steinberg SM; Balis FM
    Neuro Oncol; 2014 May; 16(5):707-18. PubMed ID: 24500418
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A chance to cut is a chance to cure: complete resection of an atypical neurofibroma prevents further progression to malignancy.
    Vaassen P; Feldkamp A; Scholz M; Blau T; Dürr NR; Rosenbaum T
    Childs Nerv Syst; 2023 Nov; 39(11):3301-3304. PubMed ID: 37344677
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Concomitant variants in NF1, LZTR1 and GNAZ genes probably contribute to the aggressiveness of plexiform neurofibroma and warrant treatment with MEK inhibitor.
    Cohen-Barak E; Toledano-Alhadef H; Danial-Farran N; Livneh I; Mwassi B; Hriesh M; Zagairy F; Gafni-Amsalem C; Bashir H; Khayat M; Warrour N; Sher O; Marom D; Postovsky S; Dujovny T; Ziv M; Shalev SA
    Exp Dermatol; 2022 May; 31(5):775-780. PubMed ID: 34913528
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Selumetinib: the first ever approved drug for neurofibromatosis-1 related inoperable plexiform neurofibroma.
    Mukhopadhyay S; Maitra A; Choudhury S
    Curr Med Res Opin; 2021 May; 37(5):789-794. PubMed ID: 33683166
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of selumetinib in patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: a systematic review and meta-analysis.
    Han Y; Li B; Yu X; Liu J; Zhao W; Zhang D; Zhang J
    J Neurol; 2024 May; 271(5):2379-2389. PubMed ID: 38502338
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular profiles of neurofibromatosis type 1-associated plexiform neurofibromas: identification of a gene expression signature of poor prognosis.
    Lévy P; Bièche I; Leroy K; Parfait B; Wechsler J; Laurendeau I; Wolkenstein P; Vidaud M; Vidaud D
    Clin Cancer Res; 2004 Jun; 10(11):3763-71. PubMed ID: 15173083
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Head circumference and anthropometric changes and their relation to plexiform and skin neurofibromas in sporadic and familial neurofibromatosis 1 Brazilian adults: a cross-sectional study.
    Basto DL; de Souza Vieira G; Andrade-Losso RM; Almeida PN; Riccardi VM; Rozza-de-Menezes RE; Cunha KS
    Orphanet J Rare Dis; 2022 Sep; 17(1):341. PubMed ID: 36064430
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interferon-α for unresectable progressive and symptomatic plexiform neurofibromas.
    Kebudi R; Cakir FB; Gorgun O
    J Pediatr Hematol Oncol; 2013 Apr; 35(3):e115-7. PubMed ID: 23042022
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Trametinib Induces Neurofibroma Shrinkage and Enables Surgery.
    Vaassen P; Dürr N; Röhrig A; Willing R; Rosenbaum T
    Neuropediatrics; 2019 Oct; 50(5):300-303. PubMed ID: 31141829
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Plexiform neurofibromas in NF1: toward biologic-based therapy.
    Packer RJ; Gutmann DH; Rubenstein A; Viskochil D; Zimmerman RA; Vezina G; Small J; Korf B
    Neurology; 2002 May; 58(10):1461-70. PubMed ID: 12041525
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.
    Robertson KA; Nalepa G; Yang FC; Bowers DC; Ho CY; Hutchins GD; Croop JM; Vik TA; Denne SC; Parada LF; Hingtgen CM; Walsh LE; Yu M; Pradhan KR; Edwards-Brown MK; Cohen MD; Fletcher JW; Travers JB; Staser KW; Lee MW; Sherman MR; Davis CJ; Miller LC; Ingram DA; Clapp DW
    Lancet Oncol; 2012 Dec; 13(12):1218-24. PubMed ID: 23099009
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Selumetinib in the Treatment of Orbital Plexiform Neurofibroma: A Case Report.
    Dai YL; Choi CS; Wiltsie L; Callahan AB
    Ophthalmic Plast Reconstr Surg; 2023 May-Jun 01; 39(3):e75-e78. PubMed ID: 36807287
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prevalence of plexiform neurofibroma in children and adolescents with type I neurofibromatosis.
    Darrigo LG; Geller M; Bonalumi Filho A; Azulay DR
    J Pediatr (Rio J); 2007; 83(6):571-3. PubMed ID: 18046492
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Superimposed Mosaicism in the Form of Extremely Extended Segmental Plexiform Neurofibroma Caused by a Novel Pathogenic Variant in the NF1 Gene.
    Veres K; Bene J; Hadzsiev K; Garami M; Pálla S; Happle R; Medvecz M; Szalai ZZ
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569527
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas.
    Kim A; Gillespie A; Dombi E; Goodwin A; Goodspeed W; Fox E; Balis FM; Widemann BC
    Neurology; 2009 Oct; 73(16):1273-9. PubMed ID: 19841379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.